The following slide deck was published by Jasper Therapeutics, Inc. in conjunction with this event.
Jasper Therapeutics (JSPR) is reporting positive updated clinical data from Jasper’s BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with CSU, as well as from the open label ...
67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label ...
Thank you for standing by. Welcome to the Jasper Therapeutics Chronic Urticaria Data Update Webinar. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made ...
REDWOOD CITY, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel ...
67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results